Basic principles of intravenous immunoglobulin (IVIg) treatment (Journal of Neurology (2006) 253, (SUPPL. 5) (18-24) DOI: 10.1007/s00415-006-5003-1);Basic principles of intravenous immunoglobulin (IVIg) treatment

Journal of Neurology

Volumn 253, Issue SUPPL. 5, 2006, Pages 308-

  Stangel, Martin ^a   Pul, Refik ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Immune treatment; Immunomodulation; Intravenous immunoglobulins; IVIg; Mechanism of action

Indexed keywords

IMMUNOGLOBULIN;

AGAMMAGLOBULINEMIA; ANTIBODY PRODUCTION; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT SYSTEM; CONFERENCE PAPER; DERMATOMYOSITIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; MACROPHAGE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUROLOGIC DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 33748975332     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0881-z     Document Type: Erratum

References (71)

1. Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104(Suppl 1):10-20
2. Aukrust P, Froland SS, Liabakk N-B, Müller F, Nordoy I, Haug C, Espevik T (1994) Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136-2143
3. Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous administration of human g-globulin. Vox Sang 7:157-174
4. Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94:1729-1735
5. 2-mediated neutralization of C3a and C3b anaphylatoxins: a novel effector function of immunoglobulins. Nature Med 9:431-438
6. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758-765
7. Behring E, Kitasato S (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113-1114
8. Berkman SA, Lee ML, Gale RP (1990) Clinical uses of intravenous immunoglobulins. Ann Intern Med 112:278-292
9. Bieber AJ, Warrington A, Pease LR, Rodriguez M (2001) Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 24(Suppl):S39-S44
10. Bouhlal H, Hocini H, Quillent-Grégoire C, Donkova V, Rose S, Amara A, Longhi R, Haeffner-Cavaillon N, Beretta A, Kaveri SV, Kazatchkine MD (2001) Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 166:7606-7611
11. Bruton OC (1952) Agammaglobulinemia. Pediatrics 9:722-728
12. Ciric B, Van Keulen V, Paz Soldan M, Rodriguez M, Pease LR (2004) Antibody-mediated remyelination operates through mechanism independent of immunomodulation. J Neuroimmunol 146:153-161
13. Devathasan G, Kueh YK, Chong PN (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 2:809-810
14. Dwyer JM (1992) Manipulating the immune system with immune globulins. N Engl J Med 326:107-116
15. Fateh-Moghadam A, Besinger U, Geursen RG (1982) Ein klinisches Modell zur Regulation der humoralen Immunantwort: Infusionstherapie. Beitr Infusionsther Klin Ernähr 9:69-79
16. Fateh-Moghadam A, Wick M, Besinger U, Geursen RG (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1:848-845
17. Frank MM, Basta M, Fries LF (1992) The effect of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 62:S82-S86
18. Gajdos P, Outin H, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphael JC, Goulon M, Goulon-Goeau C, Morel E (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1:406-407
19. Grosse-Wilde H, Blasczyk R, Westhoff U (1992) Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 39:74-77
20. Hansi W, Kratzsch G, Heimpel H (1980) Klinische Erfahrungen mit einem neuen intravenöse applizierbaren Immunglobulin-Präparat. Dtsch Med Wschr 105:1675-1680
21. Heiken H, Schmidt RE (2003) Indications for the use of immunoglobulin therapy. Dtsch Med Wochenschr 128:1665-1669
22. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani J-C, Klatzmann D, Kazatchkine MD (1994) Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (Intravenous immunoglobulin, IVIg). Ther Immunol 1:269-277
23. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228-1231
24. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegaz R (1984) High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 2:809-809
25. Jungi TW, Brcic M, Kuhnert P, Spycher MO, Li F, Nydegger UE (1990) Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 82:163-169
26. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97:865-869
27. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755
28. Kleyweg RP, van der Meche FGA, Meulstee J (1988) Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 38:1639-1641
29. Knecht H, Baumberger M, Tobòn A, Steck A (2004) Sustained remission of CIDP associated with Evans syndrome. Neurology 63:730-732
30. 2+-dependent signal transduction through Fcg receptors in B lymphocytes. Scand J Immunol 40:37-42
31. Kornhuber B (1971) Intravenöse g-Globulin-Therapie. Erfahrungen mit einer neuartigen Präparation. Mschr Kinderheilk 119:528-530
32. Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P (2004) IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 127:2649-2656
33. Lenercept Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465
34. Luthardt T (1980) Intravenöse Immunglobulinsubstitution bei Antikörpermangelsyndrom. Dtsch Med Wochenschr 105:993-997
35. n-IgG complexes. Blood 88:184-193
36. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB (1992) Human autoantibodies reactive with synthetic autoantigens from T-cell receptor b chain. Proc Natl Acad Sci 89:3325-3329
37. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Conner PW, for the International Natalizumab Multiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23
38. Mollnes TE, Hogasen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M (1995) Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding properties. Scand J Immunol 41:449-456
39. Morell A, Skvaril F (1980) Struktur und biologische Eigenschaften von Immunglobulinen und g-Globulin-Präparaten. Schweiz med Wschr 110:80-85
40. NIH consensus conference (1990) Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 264:3189-3193
41. Nobile-Orazio E (2005) Treatment of dysimmune neuropathies. J Neurol 252:385-395
42. Nolte MT, Pirofsky B, Gerritz GA, Golding B (1979) Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36:237-243
43. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM, Low PA, Romme LJ, Johnson M, An K-N, Rodriguez M (2000) IV immunoglobulin does not reverse established weakness in MSA double-blind, placebo-controlled trial. Neurology 55:1135-1143
44. Otten A, Vermeulen M, Bossuyt PMM (1995) Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 59:359-361
45. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225-230
46. Prasad NKA, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781-3790
47. Pul R, Nguyen D, Schmitz U, Marx P, Stangel M (2002) Comparison of intravenous immunoglobulin preparations on microglial function in vitro: More potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin Neuropharmacol 25:254-259
48. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, University consortium expert panel (1995) Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 273:1865-1870
49. Rossi F, Kazatchkine MD (1989) Anti-idiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 143:4104-4109
50. Rothfelder U, Neu I, Pelka R (1982) Therapie der Multiplen Sklerose mit Immunglobulin G Münch med Wschr 124:74-78
51. Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-486
52. Schuller E, Govaerts A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 22:205-212
53. Schultze HE, Schwick G (1962) Über neue Möglichkeiten intravenöser Gammaglobulin-Applikation. Dtsch Med Wschr 87:1643-1650
54. Stangel M, Bernard D (2003) Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination. J Neuroimmunol 138:25-30
55. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) A placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89-92
56. Stangel M, Compston A, Scolding NJ (1999) Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. J Neuroimmunol 96:228-233
57. Stangel M, Gold R (2004) Use of i. v. immunoglobulins in neurology - evidence-based consensus. Nervenarzt 75:801-815
58. Stangel M, Joly E, Scolding NJ, Compston DAS (2000) Normal polyclonal immunoglobulins ("IVIg") inhibit microglial phagocytosis in vitro. J Neuroimmunol 106:137-144
59. Stangel M, Schumacher HC, Ruprecht K, Boegner F, Marx P (1997) Immunoglobulins for intravenous use inhibit TNFα cytotoxicity in vitro. Immunol Invest 26:569-578
60. Stephan W (1975) Undegraded human immunoglobulin for intravenous use. Vox Sang 28:422-437
61. Stohl W, Elliot JE (1996) In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol 79:122-133
62. Takei S, Arora YK, Walker SM (1993) Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 91:602-607
63. Toungouz M, Denys CH, De Groote D, Dupont E (1995) In vitro inhibition of tumour necrosis factor-α and interleukin-6 production by intravenous immunoglobulins. B J Haematol 89:698-703
64. Toyoda M, Pao A, Petrosian A, Jordan SC (2003) Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 3:156-166
65. van der Meche FGA, Schmitz PIM, the Dutch Guillain-Barré study group. (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326:1123-1129
66. Vassilev T, Gelin C, Kaveri SV, Zilber M-T, Boumsell L, Kazatchkine MD (1993) Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 92:369-372
67. Vassilev TL, Kazatchkine MD, Van Huyen JP, Mekrache M, Bonnin E, Mani JC, Lecoubier C, Korinth D, Baruch D, Schriever F, Kaveri SV (1999) Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93:3624-3631
68. Vermeulen M, van der Meche FGA, Speelman JD, Weber A, Busch HFM (1985) Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 70:317-326
69. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat J-H, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493
70. Xu C, Poirier B, Van Huyen J-PD, Lucciari N, Michel O, Chevalier J, Kaveri S (1998) Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins. A possible mechanism of action in vascular diseases. Am J Pathol 153:1257-1266
71. Yu Z, Lennon VA (1999) Mechanism of intravenous immune globulin therapy in antibody-mediated diseases. N Engl J Med 340:227-228